Glenmark Pharma drops after 3-day 8.2% rally

Glenmark Pharmaceuticals Ltd today said its subsidiary has received approval from the US health regulator to sell generic versions of AstraZeneca's Zomig and Zomig ZMT tablets, a migraine drug, in the American market.

Brokerage house FinQuest Securities has maintained its 'Hold' rating on Glenmark Pharmaceuticals with a price target Rs 536, in its May 13, 2013 research report. The stock is fairly valued at the current price and there is limited room for further upside.

Glenmark Pharmaceuticals at the meeting of the board of directors held on May 07, 2013, Mr. Marshall Mendonza - Vice President Company Secretary ceased to be the Company Secretary of the Company consequent to his retirement. At the same meeting, Mr. Sanjay ...

Vijay told CNBC-TV18, Glenmark is a buy on all declines. It is one of the best pharma stocks in the country. If you look at their business model it is so complete, whether it is new drug discoveries, whether its domestic delivery in the formulations ...

Glenmark Pharmaceuticals Ltd has announced that the Board of Directors of the Company at its meeting held on May 07, 2013, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the ...

Glenmark Pharmaceuticals is well on its way to becoming a large-cap stock, believe analysts.

MUMBAI: Glenmark Pharmaceuticals is likely to report a net profit of Rs 160 crore, up 7 per cent, for the quarter four compared to a net profit of Rs 150 crore in year-ago period, says an . The company's revenues are seen growing 20 per cent to Rs ...

Glenmark Pharmaceuticals Ltd could miss January-March earnings consensus forecast, according to Thomson Reuters StarMine data. StarMine's SmartEstimates, which places greater emphasis on forecasts

The Delhi High Court on Friday sought response of Glenmark Pharmaceuticals on US drug major Merck Sharp and Dohme's appeal against the single judge bench order refusing to restrain the Indian firm from manufacturing and selling anti-diabetes drugs ...